- Home
- SWIN vs VNDA Comparison
SWIN vs VNDA Comparison
Compare SWIN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- VNDA
- Stock Information
- Founded
- SWIN 2017
- VNDA 2002
- Country
- SWIN Hong Kong
- VNDA United States
- Employees
- SWIN N/A
- VNDA N/A
- Industry
- SWIN
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- VNDA Health Care
- Exchange
- SWIN Nasdaq
- VNDA Nasdaq
- Market Cap
- SWIN 258.0M
- VNDA 249.4M
- IPO Year
- SWIN 2023
- VNDA 2006
- Fundamental
- Price
- SWIN $2.60
- VNDA $4.51
- Analyst Decision
- SWIN
- VNDA Strong Buy
- Analyst Count
- SWIN 0
- VNDA 2
- Target Price
- SWIN N/A
- VNDA $16.50
- AVG Volume (30 Days)
- SWIN 1.5M
- VNDA 404.6K
- Earning Date
- SWIN 06-30-2025
- VNDA 11-05-2025
- Dividend Yield
- SWIN N/A
- VNDA N/A
- EPS Growth
- SWIN N/A
- VNDA N/A
- EPS
- SWIN N/A
- VNDA N/A
- Revenue
- SWIN $3,316,000.00
- VNDA $203,467,000.00
- Revenue This Year
- SWIN $29.79
- VNDA $15.45
- Revenue Next Year
- SWIN $54.60
- VNDA $37.82
- P/E Ratio
- SWIN N/A
- VNDA N/A
- Revenue Growth
- SWIN N/A
- VNDA 11.78
- 52 Week Low
- SWIN $1.16
- VNDA $3.81
- 52 Week High
- SWIN $5.09
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- SWIN 35.67
- VNDA 46.90
- Support Level
- SWIN $2.60
- VNDA $4.54
- Resistance Level
- SWIN $3.04
- VNDA $4.64
- Average True Range (ATR)
- SWIN 0.45
- VNDA 0.15
- MACD
- SWIN -0.13
- VNDA -0.01
- Stochastic Oscillator
- SWIN 10.08
- VNDA 8.89
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.